VERQUVO®

(vericiguat) tablets 2.5 mg, 5 mg, 10 mg

Dosing With VERQUVO® (vericiguat)

VERQUVO is a convenient once-daily treatment

Start with 2.5 mg once daily Double the dose approximately every 2 weeks Reach the target dose of 10 mg once daily, as tolerated by the patient 2.5 mg 5 mg 10 mg

Pill images shown are for illustrative purposes only. These do not reflect actual size and appearance of pills.

VERQUVO should be taken with food. For patients who are unable to swallow whole tablets, VERQUVO may be crushed and mixed with water immediately before administration.

No dosage adjustment of VERQUVO is required in patients who:

No Dosage Adjustment of VERQUVO® (vericiguat) Is Required in Patients Who Have Mild or Moderate Hapatic Impairment, are Geriatric, or Have Renal Impairment Have renal impairment (eGFR ≥15 mL/min/1.73 m 2 [and are not on dialysis]) Have mild or moderate hapatic impairment VERQUVO has not been studied in patients with severe hepatic impairment Are geriatric Note that greater sensitivity of some older individuals cannot be ruled out VERQUVO has not been studied in patients with eGFR <15 mL/min/1.73 m 2 or on dialysis

Additional dosing and administration information

Obtain a pregnancy test in females of reproductive potential prior to initiating treatment with VERQUVO.

Indications and Usage

VERQUVO is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.

Selected Safety Information

WARNING: EMBRYO-FETAL TOXICITY

Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment. Do not administer VERQUVO to a pregnant female because it may cause fetal harm.

  • VERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators.

  • VERQUVO is contraindicated in pregnancy.

  • Embryo-Fetal Toxicity: Based on data from animal reproduction studies, VERQUVO may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus. Obtain a pregnancy test before the start of treatment. Advise females of reproductive potential to use effective contraception during treatment with VERQUVO and for at least one month after the final dose.

  • In a clinical trial, the most commonly observed adverse events with VERQUVO vs placebo, occurring at a frequency ≥5%, were hypotension (16% vs 15%) and anemia (10% vs 7%).

  • Concomitant use of VERQUVO with PDE-5 inhibitors is not recommended due to the potential for hypotension.

  • There are no data on the presence of vericiguat in human milk, the effects on the breastfed infant, or effects on milk production. Because of the potential for serious adverse reactions in breastfed infants from VERQUVO, advise women not to breastfeed during treatment with VERQUVO.

Before prescribing VERQUVO, please read the accompanying Prescribing Information, including the Boxed Warning about embryo-fetal toxicity. The Medication Guide also is available.

US-VER-0095008/21